While abuse deterrent formulations purportedly meet the FDA demand for safer opioid medications, their expense has been rarely supported by third party payors. Dr. Schatman reviews the reimbursement picture, the evidence for their effectiveness, and how prescribers can best respond.
Did you enjoy this article?
Subscribe to the PAINWeek Newsletter
and get our latest articles and more direct to your inbox